ANZCTR search results

The purpose of this study is to implement and evaluate a health promotion campaign on social media, which aims to raise awareness of the potential impacts of e-cigarette (vaping) use among Australian youths. The campaign aims to use three types of messages to: - raise awareness of the potential impact of e-cigarette use on health outcomes - raise awareness of the potential impact of e-cigarette use on the environment - raise awareness of unethical industry behaviour promoting vaping The outcomes will assess overall engagement with social media message content, comparing engagement across different messages.

This study involves real-time molecular profiling of brain or other CNS tumours by analysing tumour tissue, cerebrospinal fluid (CSF), and blood plasma at critical points throughout cancer diagnosis, treatment, and recurrence. Molecular profiling is like taking a detailed snapshot of a tumour's genetic makeup, helping doctors identify specific changes or mutations to guide effective treatment choices. Who is it for? You may be eligible for this study if you are a male or female age 18 or older with a known or strong suspicion of primary CNS cancer, suitable for systematic treatment. Study details Biospecimens including tumour tissue, blood and cerebrospinal fluid (CSF) will be collected longitudinally from participants during routine care procedures and/or by accessing stored material. Clinical data will be collected throughout the study. Biospecimens collected will be molecularly profiled. Molecular profiling analysis will include targeted panel sequencing, whole genome transcriptome sequencing and methylation array using tumour tissue samples. Results will be returned to the treating clinicians, accompanied by interpretation and recommendations from the molecular tumour board. By integrating clinical, molecular, histopathological, and radiological data, the project seeks to improve patient outcomes and establish feasibility of molecular profiling in CNS tumours.

The primary purpose of this study is to demonstrate the safety of the use of non steroidal medication in women who have high blood pressure (hypertension) in pregnancy. Traditionally the use of non steroidal medication has been avoided due to theoretical concerns of exacerbating preexisting hypertension. The hypothesis is that there is no increase in events of severe hypertension that would occur in the postpartum population and actually it is an effective pain killer and avoids the need for stronger pain killers like endone.

This study will evaluate a diagnostic test for cancer risk before surgery women with an ovarian mass Who is it for? You may be eligible to join this study if you are aged 18 years and above and have an ovarian cyst or adnexal mass (simple, complex, or solid ovarian/pelvic mass) identified through imaging examination that requires surgery. You will already have had a CA125 test and a transvaginal ultrasound, and your doctor will have made a decision to send you to a specialist for further examination. Study details Cleo Diagnostics Ltd has developed a novel Ovarian Cancer Adnexal Mass Assessment Score test system. Participants in this study will have a single blood sample taken prior to surgery for testing using the novel Ovarian Cancer Adnexal Mass Assessment Score test system. This test measures five analytes in serum, and combines their values into a single score. This score indicates the likelihood that a mass might be malignant, before surgery is undertaken to determine the nature of the mass. In this trial the risk score will be compared to pathology findings after surgery, to retrospectively assess its accuracy to predict malignancy. It is hoped that the test will enhance clinical decision-making and assist in patient referral for further surgical exploration.

The aim of this study is to develop a mixed reality-based exposure and response prevention intervention (MERP) that targets contamination fears and to assess its feasibility and acceptability in a clinical OCD sample. A secondary aim of this study is to explore whether MERP increases the acceptability of in vivo exposure and response prevention (ERP). We hypothesise that participants will find MERP acceptable, immersive, and able to elicit contamination fears (i.e., feasible). We also hypothesise that acceptability of MERP is positively associated with the acceptability of in vivo ERP. This study is a single-arm pilot study (Phase I Clinical Trial).

Diet has been identified as a risk factor in ulcerative colitis. Understanding the habitual diet of people with ulcerative colitis is therefore important. Protein supplementation has become increasingly popular to optimise dietary protein intakes across the general population however data on protein supplement use in ulcerative colitis has not been examined. It is hypothesised that people with ulcerative colitis are consuming protein supplements for perceived health benefits.

Children diagnosed with autism can experience difficulties expressing and communicating their emotions, which can be linked to later mental health difficulties. There is evidence that a parent emotion coaching program, called Tuning in to Toddlers, can improve a parent's ability to respond to their child's emotions and impact child behaviours; however, it is unknown whether this program would be suitable for children diagnosed with autism. The purpose of this feasibility pilot is to understand whether it is feasible to deliver this program to families of very young autistic children and family's perspectives and acceptability of this program.

The study will be conducted in one cohort of participants. The study will consist of multiple periods: a screening period (Day -28 to Day -2), radiprodil period (Day -1 to Day 5 pre-rabaprazole dose), a rabeprazole run-in period (Day 5 rabeprazole dose to Day 9 pre-radiprodil dose), a combined rabeprazole and radiprodil period (Day 9 radiprodil dose to Day 13). Participants will be discharged on Day 13 (end of study).

The overall aim of this study is to evaluate the clinical and economic impact and implementation of a service model (intervention) delivered by community pharmacists in New South Wales (NSW) and 15 pharmacies in the Australian Capital Territory (ACT), managing four skin conditions for individuals presenting with a suspected diagnosis – Impetigo, Atopic Dermatitis, Mild Plaque Psoriasis and Herpes Zoster. The specific objectives of this study are to: - Assess implementation uptake of the intervention including the reach, fidelity and adoption of the intervention in community pharmacies, participant characteristics, and variation in uptake by geographic region. - Assess the clinical outcomes and patient experience for patients managed by community pharmacists. - Assess the safety of the intervention and identify any risks that need to be addressed for future implementation. - Qualitatively assess the acceptability and feasibility of the intervention to pharmacists, other care providers and participants using the service. - Identify contextual enablers and constraints to access, adoption, fidelity, delivery, impact, sustainability, and generalisability of the intervention. - Conduct a health economic evaluation to determine the economic benefits. The study will use a cohort study design to assess the clinical and economic impact and implementation of the intervention in NSW and ACT. Pharmacies will be onboarded from June 2024 to December 2024, with the possibility to include further pharmacies in a case-by-case basis. This is due to administrative processes associated with MedAdvisor program installation, and the numbers of pharmacies that can be onboarded will be batched over this time. The study will be completed when 22,857 consults are reached or on 28 February 2025, whichever occurs first. The intervention is multicomponent including Pharmacist training and support, and a Pharmacist-patient consultation, using an IT program, applying clinical guidelines. Pharmacies and pharmacists must meet the criteria of an ‘approved pharmacy’ and an ‘approved pharmacist’ outlined in the NSW Health Authority, or a licence in ACT, to participate. Pharmacists and pharmacies will be provided follow up support as part of a translational/implementation strategy. Practice change facilitators will visit/contact these pharmacies during the study to provide ongoing support, answer any queries, ensure quality data is being collected, and collect implementation data. Pharmacies will be divided into low, medium and high contact, and this will depend on the number and nature of consultations delivered throughout the trial period. The primary outcome will be symptom resolution/relief (completely resolved, improvement, no improvement or worsening) (based on self-report at 7-day or a 14 day follow up (depending on the skin condition)). This will be a composite measure based on patient self-reported data.

This study aims to see how group-based self-instructional training, neurological music therapy, and a combination of both will affect executive functioning in people with moderate to severe traumatic brain injury.